Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy

• Status: Unknown status
• Trial end date: 2019-08-20
• Target enrollment: 0
• Participant gender: All

Summary

Bariatric surgery remains the most effective therapy for obesity. Postoperative nausea and vomiting (PONV) are commonly reported following bariatric surgery. The proposed study focuses on the most common bariatric procedure performed, laparoscopic sleeve gastrectomy (LSG), and aims to assess the effect of a post-operative nausea and vomiting-specific intervention. The investigators hypothesize that the intervention group will experience a reduction of nausea-related prolonged hospital stay and significantly improve patient-reported quality of recovery from surgery and quality of life.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Stony Brook University
• Treatments: Anesthetics; Aprepitant; BB 1101; Butylscopolammonium Bromide; Desflurane; Dexamethasone; Dexamethasone acetate; Dexmedetomidine; Fentanyl; Fosaprepitant; Metoclopramide; Ondansetron; Prochlorperazine; Propofol; Scopolamine; Scopolamine Hydrobromide; Sevoflurane

Criteria

Inclusion Criteria:

• Adult patients (18 years and older) undergoing LSG

Exclusion Criteria:

• Allergy to medications delineated in the protocol (muscle blockade, anesthetics, reversal agents)

• Inability to provide informed consent

• History of chronic nausea and emesis requiring medication

• Poorly controlled diabetes (HgA1c>9 mg/dl),

• History of previous bariatric or gastro-esophageal surgery